When Horst Lindhofer started research on bispecific antibodies in cancer treatment, he could not have expected that many years later, the drug developed from this research would be so beneficial to cancer patients. The drug, called Removab, inhibits painful fluid build-up in the abdomen.
‘Bispecific antibodies fascinated me because they could become a promising anti-cancer therapy,’ says Horst Lindhofer. Antibodies are small Y-shaped proteins that detect foreign objects in the body, such as bacteria, viruses and cancer cells. As early as 1985, bispecific antibodies that are artificially made for medical purposes were described as an effective anti-cancer therapy in vitro. While normal antibodies bind to only one target, bispecific antibodies can bind to two targets simultaneously. These bispecific antibodies were engineered to bind simultaneously to a T-lymphocyte (important cell in immune system) and a tumour cell.
For whole article please register, is free.